|
136
|
322
|
3sn7A |
Highly potent, selective, and orally active phosphodiestarase 10a inhibitors |
|
139
|
327
|
3sl8A |
Crystal structure of the catalytic domain of pde4d2 with compound 10o |
|
114
|
325
|
3shyA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
115
|
323
|
3sieA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
137
|
324
|
2ounA |
Crystal structure of pde10a2 in complex with amp |
|
138
|
325
|
2ouvA |
Crystal structure of pde10a2 mutant of d564n |
|
137
|
324
|
2oupA |
Crystal structure of pde10a |
|
128
|
324
|
5k32A |
Pde4d crystal structure in complex with small molecule inhibitor |
|
127
|
315
|
5b4kA |
Crystal structure of the catalytic domain of human pde10a complexed with n-(4-((5-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl)oxy)phenyl)-1h-benzimidazol-2-amine |
|
129
|
315
|
5axpA |
Crystal structure of the catalytic domain of pde10a complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one |
|
132
|
315
|
5axqA |
Crystal structure of the catalytic domain of pde10a complexed with highly potent and brain-penetrant pde10a inhibitor with 2-oxindole scaffold |
|
127
|
313
|
5edgA |
Human pde10a in complex with 3-(2-chloro-5-phenyl-3h-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1h-pyridazin-4-one at 2.30a |
|
125
|
320
|
5ediB |
Human pde10a, 6-chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2h-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20a, h3, rfree=23.5% |
|
125
|
314
|
5edeA |
Human pde10a in complex with 1-(4-chloro-phenyl)-3-methyl-1h-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2a |
|
124
|
315
|
5edgB |
Human pde10a in complex with 3-(2-chloro-5-phenyl-3h-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1h-pyridazin-4-one at 2.30a |
|
123
|
312
|
5edhA |
Human pde10a, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine, 2.03a, h3, rfree=22.7% |
|
128
|
315
|
5edeB |
Human pde10a in complex with 1-(4-chloro-phenyl)-3-methyl-1h-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2a |
|
123
|
313
|
5ediA |
Human pde10a, 6-chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2h-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20a, h3, rfree=23.5% |
|
125
|
307
|
5dh4A |
Pde10 complexed with 5-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine |
|
124
|
323
|
5dh5A |
Pde10 complexed with n-[(1-methylpyrazol-4-yl)methyl]-5-[[(1s,2s)-2-(2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine |
|
129
|
323
|
4zo5A |
Pde10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)isoindoline-1,3-dione |
|
129
|
322
|
4y8cA |
Crystal structure of phosphodiesterase 9 in complex with (s)-c33 |
|
124
|
322
|
4y87A |
Crystal structure of phosphodiesterase 9 in complex with (r)-c33 (6-{[(1r)-1-(4-chlorophenyl)ethyl]amino}-1-cyclopentyl-1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-one) |
|
130
|
322
|
4y86A |
Crystal structure of pde9 in complex with racemic inhibitor c33 |
|
138
|
318
|
4y2bA |
Co-crystal structure of 3-ethyl-2-(isopropylamino)-7-(pyridin-3-yl)thieno[3,2-d]pyrimidin-4(3h)-one bound to pde7a |
|
130
|
324
|
4xy2A |
Crystal structure of pde10a in complex with asp9436 |
|
130
|
347
|
4wcuA |
Pde4 complexed with inhibitor |
|
122
|
324
|
4wn1A |
Crystal structure of pde10a in complex with 1-methyl-5-(1-methyl-3-{[4-(quinolin-2-yl)phenoxy]methyl}-1h-pyrazol-4-yl)pyridin-2(1h)-one |
|
166
|
492
|
4x0fA |
Crystal structure of crosslink stabilized long-form pde4b in complex with (r)-(-)-rolipram |
|
131
|
322
|
4w1oA |
Pde4d complexed with inhibitor |
|
171
|
492
|
4wziA |
Crystal structure of crosslink stabilized long-form pde4b |
|
123
|
305
|
4tppA |
2-(3-alkoxy-1-azetidinyl) quinolines as novel pde10a inhibitors |
|
115
|
303
|
4tpmA |
Crystal structure of 2-(3-alkoxy-1-azetidinyl) quinolines as pde10a inhibitors |
|
133
|
322
|
4qgeA |
Phosphodiesterase-9a in complex with inhibitor wyq-c36d |
|
137
|
318
|
4pm0A |
Pde7a catalytic domain in complex with 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3h)-one derivative |
|
127
|
307
|
4p0nA |
Crystal structure of pde10a with a novel imidazo[4,5-b]pyridine inhibitor |
|
122
|
305
|
4phwA |
Crystal structure of pde10a with 1h-benzimidazol-2-yl(4-((3-(tetrahydro-2h-pyran-4-yl)-2-pyridinyl)oxy)phenyl)methanone |
|
133
|
318
|
4p1rA |
Crystal structure of pde10a with imidazo[4,5-b]pyridines as potent and selective inhibitors |
|
138
|
330
|
4phlA |
Tbrpdeb1-inhibitor complex |
|
125
|
324
|
4oewA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
139
|
359
|
4nw7A |
Pde4 catalytic domain |
|
134
|
328
|
4ogbA |
Crystal structure of the catalytic domain of pde4d2 with compound 2 |
|
123
|
327
|
4oexA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
137
|
352
|
4npvA |
Crystal structure of human pde1b bound to inhibitor 7a (6,7,8-trimethoxy-n-(pentan-3-yl)quinazolin-4-amine) |
|
138
|
353
|
4npwA |
Crystal structure of human pde1b bound to inhibitor 19a (7,8-dimethoxy-n-[(2s)-1-(3-methyl-1h-pyrazol-5-yl)propan-2-yl]quinazolin-4-amine) |
|
142
|
357
|
4myqA |
Selective inhibition of the catalytic domain of human phosphodiesterase 4b with a-33 |
|
136
|
331
|
4lm3A |
Crystal structure of pde10a2 with fragment zt464 |
|
132
|
328
|
4mscA |
Crystal structure of pde10a2 with fragment zt1595 (2-[(quinolin-7-yloxy)methyl]quinoline) |
|
136
|
330
|
4msaA |
Crystal structure of pde10a2 with fragment zt0449 (5-nitro-1h-benzimidazole) |
|
118
|
326
|
4md6A |
Crystal structure of pde5 in complex with inhibitor 5r |
